Firefly Neuroscience has raised $8.8 million from warrant exercises to advance its brain health technology.
Quiver AI Summary
Firefly Neuroscience, Inc. has announced the successful exercise of warrants resulting in total proceeds of $8,824,710 for the purchase of 1,623,530 shares of its common stock. These warrants were issued during private placements in August and December 2024, and the funds will be allocated for general working capital, including the company's initiative to create a foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology. Firefly's Executive Chairman, Greg Lipschitz, expressed gratitude to shareholders for their confidence, emphasizing that this investment has fortified the company's cash position, extending its financial runway into mid-2026. Firefly aims to enhance brain health outcomes for patients with neurological and mental disorders using its AI-driven diagnostic technology.
Potential Positives
- Firefly Neuroscience has secured $8,824,710 from the exercise of warrants, strengthening its financial position significantly.
- The company has established a cash runway well into mid-2026, allowing for sustained operations and potential growth opportunities.
- The proceeds will support the strategic initiative to build the world’s first foundation model of the human brain using its FDA-cleared Brain Network Analytics technology, indicating ongoing innovation.
- The Brain Network Analytics technology is being commercially launched, targeting pharmaceutical companies and medical practitioners, which could enhance market reach and revenue potential.
Potential Negatives
- While the exercise of warrants brought in significant proceeds, reliance on private placements for funding may indicate potential liquidity concerns in the future.
- The mention of forward-looking statements highlights inherent risks and uncertainties associated with the company's projections, which could lead to stakeholder skepticism.
- The press release does not provide specific details about how the funds will be allocated beyond 'general working capital,' which may raise concerns about financial transparency.
FAQ
What is the recent financial announcement by Firefly Neuroscience?
Firefly Neuroscience announced total proceeds of $8,824,710 from the exercise of warrants for 1,623,530 shares of common stock.
How will Firefly use the proceeds from the warrant exercises?
The proceeds will be used for general working capital purposes, including developing their Brain Network Analytics (BNA™) technology.
What is Firefly's Brain Network Analytics technology?
BNA™ is an FDA-cleared technology that enhances diagnostic and treatment monitoring for neurological and mental disorders using AI and machine learning.
What are the conditions targeted by Firefly's BNA™ technology?
BNA™ primarily targets conditions like depression, dementia, anxiety disorders, concussions, and ADHD, providing insights into brain function.
How has Firefly established its position in the market?
Firefly has built a comprehensive database of brain wave tests and achieved FDA clearance, positioning itself as a leader in brain health solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
KENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announced that it has received total proceeds of $8,824,710 from the exercise of warrants to purchase 823,530 shares of the common stock of the Company, par value $0.0001 per share (“common stock”), at an exercise price of $6.83, and warrants to purchase 800,000 shares of commons stock, at an exercise price of $4.00, respectively. The warrants were issued pursuant to private placements that closed on August 12, 2024 and December 20, 2024, and no new warrants were issued by the Company as a result of the exercises.
The proceeds from the exercise of the warrants will be used for general working capital purposes, including Firefly’s
recently announced
strategic initiative to build the world’s first foundation model of the human brain using its U.S. Food and Drug Administration (FDA)-cleared Brain Network Analytics (“BNA™”) technology platform.
“I want to thank our shareholders for such a strong vote of confidence in our ability to unleash the power of our FDA-cleared BNA™ technology,” said Greg Lipschitz, Executive Chairman of Firefly. “The warrant exercises have significantly strengthened our current cash position, and we are now in the enviable position of having cash runway well into mid-2026.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, secured patent protection, and achieved FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit
https://fireflyneuro.com/
for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
